ARUP Licenses Epigenomics' Cancer Biomarker | GenomeWeb

NEW YORK (GenomeWeb news) – ARUP Laboratories, a diagnostic testing services provider in Salt Lake City, has licensed a biomarker from Epigenomics for use in developing an early detection test for colorectal cancer.

Berlin, Germany-based Epigenomics said today that ARUP has signed a non-exclusive license to use the DNA methylated Septin 9 gene to develop a test for colorectal cancer from a patient's blood sample.

The company said that it has demonstrated that methylated DNA of the Septin 9 gene indicates colorectal cancer in the early stages.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.